[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"recurrent-bacterial-vaginosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:recurrent-bacterial-vaginosis":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,67],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100629450","evaluation-of-the-ability-of-lactobacillus-crispatus-crp21-to-reduce-the-incidence-of-recurrent-bacterial-vaginosis-100629450",false,"NCT07474831","Evaluation of the Ability of Lactobacillus Crispatus CRP21 to Reduce the Incidence of Recurrent Bacterial Vaginosis","Evaluation of the Ability of Lactobacillus Crispatus CRP21 to Reduce the Incidence of Recurrent Bacterial Vaginosis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial","Inclusion Criteria:\n\n* Female participants aged 18 to 45 years\n* Diagnosis of recurrent bacterial vaginosis\n* At least three documented episodes of bacterial vaginosis in the previous 12 months\n* Completion of standard antibiotic therapy for bacterial vaginosis before enrollment\n* Willingness to comply with study procedures and follow-up visits\n* Provision of written informed consent\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding\n* Current use of systemic antibiotics or antifungal therapy not related to treatment of bacterial vaginosis\n* Known hypersensitivity to probiotic products or study components\n* Presence of other significant gynecological infections requiring treatment\n* Use of vaginal probiotic products within 30 days prior to enrollment\n* Participation in another clinical trial within the previous 30 days","FEMALE","18 Years","45 Years",{"count":20,"type":21},156,"ESTIMATED","INTERVENTIONAL",[24],"NA","Recurrent bacterial vaginosis is a common condition in women of reproductive age and is characterized by a disruption of the normal vaginal microbiota, with a reduction in Lactobacillus species and an overgrowth of anaerobic bacteria such as Gardnerella vaginalis. Recurrence rates after standard antibiotic treatment are high. Lactobacillus crispatus is considered one of the most protective species for maintaining vaginal microbiota balance.\n\nThis multicenter, randomized, double-blind, placebo-controlled clinical trial aims to evaluate the efficacy and safety of a probiotic supplement containing Lactobacillus crispatus CRP21 (Crispavag® capsules) in reducing the incidence of recurrent bacterial vaginosis in women diagnosed with recurrent bacterial vaginosis. After standard antibiotic treatment, participants will be randomly assigned in a 1:1 ratio to receive either the probiotic supplement or a placebo for 12 weeks.\n\nThe primary objective is to evaluate whether supplementation with Lactobacillus crispatus CRP21 reduces the incidence of recurrent bacterial vaginosis episodes compared with placebo. Participants will be followed for a total of 24 weeks, including a 12-week treatment period and a 12-week follow-up period.",[27],"Recurrent Bacterial Vaginosis","NOT_YET_RECRUITING","2026-03-20",{"date":31,"type":32},"2026-03-25","ACTUAL",{"date":34,"type":21},"2026-03-23",{"date":36,"type":21},"2027-04-16",{"name":38,"class":39},"Liaquat University of Medical & Health Sciences","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":40},"100366102","phase-1-vaginal-microbiota-transplant-100366102","NCT04046900","Vaginal Microbiota Transplant","Vaginal Microbiota Transplant to Promote Lactobacillus-dominant Cervicovaginal Communities","MOTIF","Inclusion Criteria:\n\n* Premenopausal women, 18- 50 years old\n* Abnormal Nugent score: \\> 3\n* History of recurrent bacterial vaginosis (BV) (3 or more documented episodes in past 12 months)\n* If participating in sexual activity that could lead to pregnancy, study participants must agree to use an effective contraceptive while actively participating in the protocol. At least one of the following methods MUST be used:\n\n  * Condoms (male or female), with or without a spermicidal agent\n  * Intrauterine device (IUD)\n  * Hormonal contraceptive (including oral pills, vaginal ring, implant, injection)\n\nExclusion Criteria:\n\n* History of clinically significant vaginal, cervical, or uterine disease including but not limited to: cancer of the female reproductive tract, prior hysterectomy, high grade cervical dysplasia (CIN III), or diagnosed with cervicovaginal infection (with the exception of bacterial vaginosis) within the 30 days prior to the procedure.\n\n  * Allergy to metronidazole\n  * Use of investigational therapies or investigational vaccines within 90 days prior to study entry\n  * Use of any immunomodulatory agents within 30 days prior to study enrollment. Subject taking any of the following medications: systemic steroids (inhaled or nasal steroid therapy is permitted), interleukins, systemic interferons (e.g. local injection of interferon alpha for treatment of HPV is permitted) or systemic chemotherapy.\n  * History of coronary artery disease, myocardial infarction, COPD, chronic renal failure, decompensated cirrhosis, or any other condition that in the opinion of the investigator will compromise ability to participate in the study.\n  * History of abnormal pap smear within 12 months\n  * Insertion of levonorgestrel-containing IUD within 3 months prior to study entry\n  * Either breastfeeding or pregnant within 24 weeks prior to study entry\n  * Use of probiotics and prebiotics (supplements and products, oral or vaginal) within 30 days of the study. (NOTE: Oral yogurt with live cultures is allowed.)\n  * Routine use of oral antibiotics i.e. daily use for acne, Hidradenitis suppurativa, or regular use for post-coital urinary tract infection prophylaxis within the past 30 days.\n  * Taken non-metronidazole antibiotics in last 30 days\n  * BMI \\> 40","50 Years",{"count":51,"type":21},62,[53,54],"PHASE1","PHASE2","This is a randomized trial of vaginal microbiome transplant vs. saline placebo to restore a Lactobacillus dominant vaginal microbial community in women with recurrent bacterial vaginosis.",[27],"RECRUITING","2025-07-15",{"date":60,"type":32},"2025-07-18",{"date":62,"type":32},"2021-04-22",{"date":64,"type":21},"2026-09-30",{"name":66,"class":39},"Douglas Kwon",{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":22,"phases":78,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":40},"100571871","evaluation-of-the-medical-device-vagitab---t-as-adjuvant-therapy-in-patients-with-bacterial-vaginosis-100571871","NCT06725888","Evaluation of the Medical Device Vagitab - T as Adjuvant Therapy in Patients With Bacterial Vaginosis.","A Prospective, Multicentre, Open-label, Study to Assess Performance and Safety of the Medical Device Vagitab - T in Rebalancing the Altered Vaginal Flora as Adjuvant Therapy in Patients With Bacterial Vaginosis and in Reducing Incidence of Recurrence During a 3-months Period of Follow-up.","Vagitab","Inclusion Criteria:\n\n* Female patients aged from 18 to 65 years (inclusive).\n* Patients affected at enrolment by BV diagnosed according to Amsel criteria, candidate to start an antibiotic therapy with metronidazole.\n* Patient with a medical history of RBV (at least 2 episodes of BV in the last 12 months including the current episode).\n* Patients who are, in the opinion of the Investigator, able to understand the study, cooperate with the study procedures and attend all the study visits.\n* Patients who have given their written informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Patient with a medical history of HIV or any other immunodeficiency.\n* Patients working as sex workers.\n* Patients with known allergies or intolerance \u002F hypersensitivity to the tested medical device and its components.\n* Patients with concomitant menstrual bleeding at baseline.\n* Time between the last day of last menses and treatment with metronidazole ≤ 3 days.\n* Pregnant, lactating, and lactating amenorrhoeic patients and patients of childbearing potential who are planning a pregnancy or unwilling to use appropriate methods of contraception during the study\n* Concomitant use of vaginal tampons.\n* Concomitant administration of etonogestrel\u002Fethinyl estradiol vaginal rings or of intrauterine devices.\n* Concomitant use of oral or vaginal antibiotic therapy (apart from metronidazole) or any other vaginal therapies or treatment (such as douching, spermicide).\n* Concomitant use of oral or vaginal probiotics.\n* Patients with any other medical condition that, in the opinion of the Investigator, would compromise participation or be likely to lead to hospitalization during the study.\n* Concomitant or previous (in the previous 30 days) participation in any other interventional clinical trials","65 Years",{"count":77,"type":21},30,[24],"This clinical trial is looking at how well and safely the vaginal administration of Vagitab-T works . Vagitab-T is already on the market in several countries in Europe as a medical device.\n\nThe main goals of this trial are to see if the recurrence rate of bacterial vaginosis goes down during the study, if it helps balance the altered vaginal flora during antibiotic treatment, if it improves vaginal secretions, and if vaginal microflora return to normal. We'll also ask the participants about their quality of life and whether they think the treatment is safe.\n\nAll 30 women will get the same treatment, and there's no comparison group. They'll be treated with Vagitab-T vaginal tablets for three monthly cycles. Also, metronidazole will be taken at the start of the study for seven days.\n\nParticipants will sign an informed written consent and we'll visit them at the start (day 0) and end (day 90) of the study. In addition, we'll call them during each of the three cycles of treatment.",[81,27],"Bacterial Vaginosis (BV)",[83,27,84,85],"Bacterial Vaginosis","Vaginal microflora","Lactobacillus","2025-05-21",{"date":88,"type":32},"2025-05-28",{"date":90,"type":32},"2025-03-31",{"date":92,"type":21},"2025-09-30",{"name":94,"class":95},"S.I.I.T. Srl","INDUSTRY"]